Efficacy, Safety, and Influence on the Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1-Positive NSCLC: A Phase II Trial (EAST ENERGY).
Aokage K, Koyama S, Kumagai S, Nomura K, Shimada Y, Yoh K, Wakabayashi M, Fukutani M, Furuya H, Miyoshi T, Tane K, Samejima J, Taki T, Hayashi T, Matsubayashi J, Ishii G, Nishikawa H, Ikeda N, Tsuboi M.
Aokage K, et al. Among authors: samejima j.
Clin Cancer Res. 2024 Dec 16;30(24):5584-5592. doi: 10.1158/1078-0432.CCR-24-1561.
Clin Cancer Res. 2024.
PMID: 39453771
Clinical Trial.